The goal of presbyopia-correcting IOL (PCIOL) technology is to provide good vision at various distances and to keep the light utilization high to preserve visual performance. How is that achieved, and what are different approaches?

Both multifocal and trifocal IOLs use diffractive optics to create more than one simultaneous image on the retina to allow the patient to see at multiple distances. The diffractive element can be located on the anterior or posterior surface of the IOL and cover a part of or the total optical area.

As multifocal and trifocal IOLs have a different number of focal points, a different approach may be used to achieve the best light utilization for each IOL type. Depending on the design intent, there are two general strategies that optimize light energy distribution of a multifocal or trifocal IOL:

1. Apodization (gradual diffractive step height change): this achieves a gradual change in light energy distribution within the diffractive zone.
2. Ratio of diffractive zone versus optic diameter: the light energy distribution remains at the same level within the diffractive zone for each focal point, but changes as soon as the pupil size is larger than the diffractive zone.

Additionally, a combination of the two general strategies may also be used.

ACRYSOF IQ RESTOR +3.0 D AND ACRYSOF IQ RESTOR +2.5 D WITH ACTIVEFOCUS OPTICAL DESIGN

The AcrySof IQ ReSTOR +3.0 D IOL and AcrySof IQ ReSTOR +2.5 D IOL with ACTIVEFOCUS optical design are aspheric, diffractive multifocal IOLs characterized by a central diffractive zone and an outer refractive zone. The diffractive zone for AcrySof IQ ReSTOR +3.0 D IOL and AcrySof IQ ReSTOR +2.5 D IOL with ACTIVEFOCUS optical design covers the central 3.6 mm (9 rings) and 3.4 mm (7 rings) diameter area, respectively. The diffractive structure diverts light simultaneously into 2 distinct focal points: 1) distance and 2) intermediate or near (depending on the add power). The outer refractive zone exclusively directs light to the distance.

The design intent for AcrySof IQ ReSTOR +3.0 D IOL and AcrySof IQ ReSTOR +2.5 D IOL with ACTIVEFOCUS optical design is to provide good distance vision with any pupil size, especially in low light conditions. Therefore, the light energy distribution for the AcrySof IQ ReSTOR +3.0 D IOL and AcrySof IQ ReSTOR +2.5 D IOL with ACTIVEFOCUS optical design are optimized using both of the two light energy management strategies, apodization, and a smaller diffractive zone. This combination allows for a gradual change in light energy distribution.

Firstly, apodization ensures good distance performance with any pupil size as it reduces optical phenomena in low light conditions. Characteristic of the apodized diffractive design is the step height that reduces from the center toward the periphery of the optic. As the step height reduces and the pupil dilates, the light energy is progressively redirected from the near focus to the distance focus. A smaller diffractive zone ensures that, for pupil sizes larger than the diffractive zone, additional light is being directed to distance to provide good distance vision in low light conditions.

PANOPTIX TRIFOCAL

The PanOptix Trifocal IOL is also an aspheric, diffractive IOL with a central diffractive zone and an outer refractive zone. The diffractive zone covers 4.5 mm (15 rings) of the central optic zone and diverts light simultaneously into 3 distinct focal points: distance, intermediate, and near. The outer refractive zone from 4.5 mm to 6.0 mm directs light to distance.
Different to the ReSTOR multifocal IOLs, the design intent for PanOptix Trifocal IOL was to provide a full range of vision, especially intermediate and near, in various lighting conditions while maintaining good distance vision. A clinical study showed that the PanOptix Trifocal IOL provides the possibility of distance, intermediate, and near vision with a visual acuity of 20/20+ or better using a binocular defocus curve, which allows for a reduced need for spectacles.

The light energy distribution for the PanOptix Trifocal IOL is therefore managed by the diffractive structure diameter. Such an approach provides consistent light energy at each of the focal points within the diffractive zone. The diffractive zone for the PanOptix Trifocal IOL was balanced at a 4.5-mm diameter to enable near and intermediate vision, as well as distance performance in low light conditions. For pupil sizes beyond the 4.5-mm diffractive zone, additional light is being directed to distance as needed for night driving.

**SUMMARY**

There are different strategies used to manage light distribution in today’s PCIOLs, and the design intent is an important deciding factor in the selection of the appropriate light management strategy.

**BRET FISHER, MD**
- Medical Director of The Laser and Surgery Center, The Eye Center of North Florida, Panama City, FL

**XIN HONG, PHD, FAAO**
- Distinguished Fellow, Surgical R&D, Alcon Inc.

**ANDREA PETZNICK, PHD**
- Associate Medical Director, North America Medical Affairs, Alcon Inc.

---

**AcrySof® IQ PanOptix® Family of Trifocal IOLS**

**IMPORTANT PRODUCT INFORMATION**

**CAUTION:** Federal (USA) law restricts this device to the sale by or on the order of a physician.

**INDICATIONS:** The AcrySof® IQ PanOptix® Trifocal IOLs include AcrySof® IQ PanOptix® and AcrySof® IQ PanOptix® Toric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the AcrySof® IQ PanOptix® Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism.

**WARNINGS/PRECAUTIONS:** Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved. For the AcrySof® IQ PanOptix® Toric Trifocal IOLs, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or starbursts, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions.

Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning).

As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO), may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the AcrySof® IQ PanOptix® Trifocal IOLs.

**ATTENTION:** Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.

**ACRYSO® IQ RESTOR® FAMILY OF INTRAOCULAR LENSES IMPORTANT PRODUCT INFORMATION**

**CAUTION:** Federal (USA) law restricts this device to the sale by or on the order of a physician.

**INDICATIONS:** The AcrySof® IQ ReSTOR® Posterior Chamber Intraocular Lens (IOL) is intended for primary implantation for the visual correction of aphakia secondary to removal of a cataractous lens in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. The lens is intended to be placed in the capsular bag.

**WARNINGS/PRECAUTIONS:** Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved. Care should be taken to remove viscoelastic from the eye at the close of surgery. Some patients may experience visual disturbances and/or discomfort due to multifocality, especially under dim light conditions. As with other multifocal IOLs, visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. Spectacle independence rates vary with all multifocal IOLs; as such, some patients may need glasses when reading small print or looking at small objects.

Clinical studies with the AcrySof® ReSTOR® lens indicated that posterior capsule opacification (PCO), when present, developed earlier into clinically significant PCO. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ ReSTOR® IOLs. Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45°C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions.

**ATTENTION:** Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.

*Based on mean value of binocular defocus curve at near, intermediate, and distance at 6 months (n = 127).

†Snellen VA was converted from logMAR VA. A Snellen notation of 20/20 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.